Connor, Clark & Lunn Investment Management (CC&L)’s Pacific Biosciences PACB Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-148,046	Closed	-$555K	–	1604
2024 Q1	$555K	Buy	+148,046	New	+$867K	﹤0.01%	1076
2021 Q1	–	Sell	-206,007	Closed	-$5.34M	–	1063
2020 Q4	$5.34M	Buy	+206,007	New	+$3.5M	0.03%	324
2015 Q4	–	Sell	-21,578	Closed	-$79K	–	853
2015 Q3	$79K	Sell	21,578 -67,300	-76%	-$329K	﹤0.01%	675
2015 Q2	$512K	Sell	88,878 -29,100	-25%	-$168K	﹤0.01%	423
2015 Q1	$689K	Sell	117,978 -110,400	-48%	-$761K	0.01%	355
2014 Q4	$1.79M	Buy	228,378 +1,000	+0.4%	+$6.4K	0.01%	240
2014 Q3	$1.12M	Buy	+227,378	New	+$1.19M	0.01%	283

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return

EDRH

Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s PACB Position: Q2 2024 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Pacific Biosciences (PACB) in Q2 2024, closing a stake of 148,046 shares — an estimated $555K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in PACB in Q3 2014 and held it in 7 quarters. The position peaked at $5.34M in Q4 2020. 228 funds tracked by Wall St. Rank hold PACB as of Q2 2024.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Pacific Biosciences position as of Q2 2024 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 148,046 Pacific Biosciences shares in Q2 2024, an estimated $555K.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Pacific Biosciences in Q3 2014 and held it in 7 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s Pacific Biosciences position peaked at $5.34M in Q4 2020.
228 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2024.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2024, filed 9 Aug 2024.